Menu
Logo

Indications for DARZALEX®[1]

DARZALEX® for multiple myeloma

Frontline transplant-eligible
Frontline transplant-ineligible
From 2nd line
From 3rd line

DARZALEX® for AL amyloidosis

Newly-diagnosed

DARZALEX® practical guides

SC Checklist beginning of treatment

Includes a first use checklist of Darzalex® SC.

Darzalex® SC Practical Guide

Includes DARZALEX® SC handling and administration info, pre and post-injection medications, and more

Dosing schedules for all Darzalex® treatment regimens

Find more about DARZALEX® and multiple myeloma

Prof. Mateos presents 4-year updates of POLLUX study

María-Victoria Mateos of Hospital Universitario de Salamanca

21 February 2020 ASH 2019

Prof. Mateos presents 4-year updates of CASTOR study

María-Victoria Mateos of Hospital Universitario de Salamanca

21 February 2020 ASH 2019

ALCYONE update

Prof. María-Victoria Mateos presents 1-year updates from ALCYONE

DARZALEX® SC practical guidance
DARZALEX® SC preparation

An interactive video covering the key facts about the handling, preparation and administration of DARZALEX® SC

DARZALEX® SC studies
DARZALEX® SC STUDIES

In this interactive video, Prof. Mateos gives an overview of the DARZALEX® SC PAVO, COLUMBA and PLEIADES studies.

Patient materials
Supporting patients on their journey

Access downloadable patient materials to help your patients and their caregivers on their journey with MM treatment

DARZALEX® is the first approved CD38‑targeting immunotherapy for multiple myeloma (MM)[2]


Glossary

AL: amyloid light chain

IRR: infusion-related reaction

MM: multiple myeloma

MOA: mode of action

Rd: lenalidomide, dexamethasone

SC: subcutaneous

VCd: Velcade®, cyclophosphamide, dexamethasone

Vd: Velcade®, dexamethasone

VMP: Velcade®, melphalan, prednisone

VTd: Velcade®, thalidomide, dexamethasone

Para visualizar o IECRCM de Darzalex, veja aqui.
CP-287814 - março 2022